A Prospective Cohort Study on the Prediction of Effectiveness of Sorafenib on the Basis of Angiogenesis-Related Cytokines
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000009771
- Lead Sponsor
- Okayama University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Not provided
1) Patients with histologically confirmed mixed-type HCC or sarcomatous change 2) Patients with a history of molecular-targeted therapy 3) Patients with active double cancer (Patients who have early-stage cancer that does not appear to affect their prognosis and can be controlled by treatment may be enrolled in this study.) 4) Patients with any serious coexisting condition (e.g., ileus, interstitial pneumonia, pulmonary fibrosis, difficult-to-control diabetes mellitus, hypertension, cardiac failure, renal failure, hepatic failure, active peptic ulcer, varicose veins in danger of rupture, severe mental disorder or depression) 5) Patients with ascites and/or pleural effusion unresponsive to treatment 6) Patients judged by the principal investigator or subinvestigator to be unsuitable for participation for any other reason (to ensure the safe conduct of this study)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method